Cargando…
Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data
INTRODUCTION: We aimed to clarify medical expenses in Japanese individuals before and after major depressive disorder (MDD) diagnosis, and to determine whether MDD treatment also reduces medical costs for comorbid physical conditions. METHODS: This was an exploratory, descriptive, retrospective anal...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989836/ https://www.ncbi.nlm.nih.gov/pubmed/34729704 http://dx.doi.org/10.1007/s12325-021-01963-9 |
_version_ | 1784683257946701824 |
---|---|
author | Cho, Yoshinori Mishiro, Izumi Fujimoto, Shinji Nakajima, Tadashi |
author_facet | Cho, Yoshinori Mishiro, Izumi Fujimoto, Shinji Nakajima, Tadashi |
author_sort | Cho, Yoshinori |
collection | PubMed |
description | INTRODUCTION: We aimed to clarify medical expenses in Japanese individuals before and after major depressive disorder (MDD) diagnosis, and to determine whether MDD treatment also reduces medical costs for comorbid physical conditions. METHODS: This was an exploratory, descriptive, retrospective analysis of insurance claims data from JMDC Inc. Cohort A included individuals aged 18–64 years between January 2015 and December 2019. Cohorts B and C included Cohort A individuals with diabetes/hypertension (‘chronic disease’), and sleep/anxiety disorders (‘high depression risk’), respectively. Individuals in Cohorts A–C with an MDD diagnosis were analyzed by year of MDD onset (Cohorts A–C(MDD2015–2019)). Diagnoses and median medical costs were derived from International Classification of Diseases 10 codes. RESULTS: Total medical and non-neuropsychiatric drug costs in MDD onset years were 170,390–182,120 and 8480–9586 yen higher, respectively, for Cohorts A(MDD2015–2019) than for Cohort A. In Cohort A(MDD2019), total medical and non-neuropsychiatric drug costs increased incrementally from 2015 to 2019 (total changes: + 165,130 and + 7365 yen, respectively), to a greater degree than in Cohort A (+ 10,510 and + 1246 yen, respectively). Neuropsychiatric drug costs increased in the year of MDD onset only and decreased thereafter. After MDD onset, decreases in total medical and non-neuropsychiatric drug costs were observed (Cohorts A(MDD2015–2019)). Non-neuropsychiatric drug costs also decreased after MDD onset in the chronic disease groups (Cohorts C(MDD)(2015–2019)), but not in patients with MDD recurrence. CONCLUSION: Treating MDD reduces medical costs for comorbid physical conditions and may be a useful strategy for improving healthcare efficiency in Japan. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01963-9. |
format | Online Article Text |
id | pubmed-8989836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-89898362022-04-22 Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data Cho, Yoshinori Mishiro, Izumi Fujimoto, Shinji Nakajima, Tadashi Adv Ther Original Research INTRODUCTION: We aimed to clarify medical expenses in Japanese individuals before and after major depressive disorder (MDD) diagnosis, and to determine whether MDD treatment also reduces medical costs for comorbid physical conditions. METHODS: This was an exploratory, descriptive, retrospective analysis of insurance claims data from JMDC Inc. Cohort A included individuals aged 18–64 years between January 2015 and December 2019. Cohorts B and C included Cohort A individuals with diabetes/hypertension (‘chronic disease’), and sleep/anxiety disorders (‘high depression risk’), respectively. Individuals in Cohorts A–C with an MDD diagnosis were analyzed by year of MDD onset (Cohorts A–C(MDD2015–2019)). Diagnoses and median medical costs were derived from International Classification of Diseases 10 codes. RESULTS: Total medical and non-neuropsychiatric drug costs in MDD onset years were 170,390–182,120 and 8480–9586 yen higher, respectively, for Cohorts A(MDD2015–2019) than for Cohort A. In Cohort A(MDD2019), total medical and non-neuropsychiatric drug costs increased incrementally from 2015 to 2019 (total changes: + 165,130 and + 7365 yen, respectively), to a greater degree than in Cohort A (+ 10,510 and + 1246 yen, respectively). Neuropsychiatric drug costs increased in the year of MDD onset only and decreased thereafter. After MDD onset, decreases in total medical and non-neuropsychiatric drug costs were observed (Cohorts A(MDD2015–2019)). Non-neuropsychiatric drug costs also decreased after MDD onset in the chronic disease groups (Cohorts C(MDD)(2015–2019)), but not in patients with MDD recurrence. CONCLUSION: Treating MDD reduces medical costs for comorbid physical conditions and may be a useful strategy for improving healthcare efficiency in Japan. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01963-9. Springer Healthcare 2021-11-02 2022 /pmc/articles/PMC8989836/ /pubmed/34729704 http://dx.doi.org/10.1007/s12325-021-01963-9 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Cho, Yoshinori Mishiro, Izumi Fujimoto, Shinji Nakajima, Tadashi Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data |
title | Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data |
title_full | Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data |
title_fullStr | Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data |
title_full_unstemmed | Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data |
title_short | Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data |
title_sort | impact of depression onset and treatment on the trend of annual medical costs in japan: an exploratory, descriptive analysis of employer-based health insurance claims data |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989836/ https://www.ncbi.nlm.nih.gov/pubmed/34729704 http://dx.doi.org/10.1007/s12325-021-01963-9 |
work_keys_str_mv | AT choyoshinori impactofdepressiononsetandtreatmentonthetrendofannualmedicalcostsinjapananexploratorydescriptiveanalysisofemployerbasedhealthinsuranceclaimsdata AT mishiroizumi impactofdepressiononsetandtreatmentonthetrendofannualmedicalcostsinjapananexploratorydescriptiveanalysisofemployerbasedhealthinsuranceclaimsdata AT fujimotoshinji impactofdepressiononsetandtreatmentonthetrendofannualmedicalcostsinjapananexploratorydescriptiveanalysisofemployerbasedhealthinsuranceclaimsdata AT nakajimatadashi impactofdepressiononsetandtreatmentonthetrendofannualmedicalcostsinjapananexploratorydescriptiveanalysisofemployerbasedhealthinsuranceclaimsdata |